Advertisement


Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

2015 ASTRO Annual Meeting

Advertisement

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).



Related Videos

Skin Cancer
Head and Neck Cancer
Breast Cancer

Catherine C. Park, MD, on Novel Clinical Paradigms

Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).

Prostate Cancer

Anthony Zietman, MD, on Accelerating Treatment: RTOG 0415 Study on Prostate Cancer

Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).

Breast Cancer

Robert Kuske, MD, on PROMIS Registry Results

Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).

Gastroesophageal Cancer
Colorectal Cancer

Leonard Gunderson, MD, on the Presidential Symposium Lecture on Upper and Lower GI Cancers

Leonard Gunderson, MD, of the Mayo Clinic College of Medicine, discusses PET/CT imaging in upper and lower gastrointestinal cancers, which can be of value as a baseline study prior to treatment, in determining the degree of response to treatment, and in helping decide whether there is a relapse after a complete response to treatment.

Prostate Cancer

Anthony Zietman, MD, on Hormonal Therapy and Salvage Radiation: Results of RTOG 9601

Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).

Advertisement

Advertisement




Advertisement